Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
393.4 USD | +0.07% | -1.64% | -3.25% |
04:21pm | Vertex Pharmaceuticals Says FDA Granted Rolling Review of Suzetrigine to Treat Acute Pain | MT |
Apr. 17 | UBS Adjusts Vertex Pharmaceuticals Price Target to $466 From $498, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.25% | 102B | |
+2.20% | 96.84B | |
-0.44% | 21.48B | |
-18.47% | 20.82B | |
-7.45% | 18.6B | |
-40.31% | 16.81B | |
-26.02% | 13.78B | |
+0.79% | 13.4B | |
+20.64% | 11.06B | |
-21.21% | 8.88B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Insider Sell: Vertex Pharmaceuticals